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Fecal incontinence (FI) is the involuntary loss of rectal contents through the anal canal. Reports of its prevalence vary from 1–21%.
Studies, have demonstrated a positive eﬀect on FI symptoms with injectable bulking agents. This study evaluated the safety and
eﬃcacy of NASHA/Dx gel in the treatment of FI. One hundred ﬁfteen eligible patients suﬀering from FI received 4 injections of
1m LN A S H A / D xg e l .P r i m a r ye ﬃcacy was based on data from 86 patients that completed the study. This study demonstrated a
≥50% reduction from baseline in the number of FI episodes in 57.1% of patients at 6 months, and 64.0% at 12 months. Signiﬁcant
improvements (P<. 001) were also noted in total number of both solid and loose FI episodes, FI free days, CCFIS, and FIQL
scores in all 4 domains. The majority of the treatment related AEs (94.9%) were mild or moderate intensity, and (98.7%) of AEs
resolved spontaneously, or following treatment, without sequelae. Results of this study indicate NASHA/Dx gel was eﬃcacious in
the treatment of FI. Treatment eﬀect was signiﬁcant both in reduction of number of FI episodes and disease speciﬁc quality of life
at 6 months and lasted up to 12 months after treatment.
1.Introduction
Fecal incontinence (FI) is the involuntary loss of rectal
contents through the anal canal [1]. Reports of its prevalence
vary from approximately 1% to 21% [2–6]. Fecal inconti-
nence aﬀects up to 8% of the adult population over the age
of 65 years [5–7]. In the elderly population both sexes are
equally aﬀected, but in younger populations, (aged 25–45)
F Ii s8t i m e sm o r ec o m m o ni nw o m e nt h a ni nm e n[ 6, 8, 9].
Obstetric trauma is recognized as a common cause.
Patients may present with FI in the postpartum period or
sometimes with an onset delay of several years. Trauma dur-
ing delivery may cause incontinence by direct rupture of the
anal sphincters or by overstretching of the pudendal nerves.
Fecal incontinence can also be caused by colorectal disease,
trauma, neurological disorders, or congenital abnormalities
[10–12].
The severity of FI may vary over time as the condition
is inﬂuenced by external factors such as physical exercise,
stress, concurrent illness, and diet. Fecal incontinence can be
a source of embarrassment for those aﬀected and has a great
negative impact on the quality of life [13].
Treatment regimens usually begin with dietary and
lifestyle modiﬁcations and pharmacotherapy such as ﬁber
therapy and antidiarrheals. Overlapping sphincteroplasty is
the most common surgical therapy for FI. This surgery2 Gastroenterology Research and Practice
works for isolated sphincter injury cases but is not indicated
in patients without sphincter injuries or in patients with
multiple sphincter defects in diﬀerent locations. Moreover,
recent studies have demonstrated that the eﬃcacy of sphinc-
teroplasty may diminish over time [14].
New surgical alternatives to overlapping sphincteroplasty
such as sacral nerve stimulation (SNS) [15–17], Secca’s
procedure [18–20], artiﬁcial bowel sphincter (ABS) [21–23],
and dynamic graciloplasty [24–26] have been developed and
are increasingly used in the treatment of FI [27].
Nonreactive bulking agents have been used successfully
in aesthetics, vesicoureteral reﬂux (VUR) in children, and
stress urinary incontinence (SUI) for many years [28–30]. As
a result, noninvasive treatment of FI with bulking agents has
developed [31] .S m a l ls t u d i e sh a v ed e m o n s t r a t e dap o s i t i v e
eﬀect on FI symptoms with a low rate of complications with
this method of treatment [32–36].
NASHA/Dx gel consists of nonanimal stabilized
hyaluronic acid and dextranomer microspheres (Solesta,
Oceana Therapeutics, Edison, NJ). It is biocompatible,
nonallergenic, and showing no sign of distant migration
of the dextranomer [37]. The material in NASHA/Dx
is identical to Deﬂux, which has been safely used for
the treatment of children suﬀering from VUR (i.e., the
retrograde ﬂow of urine from the bladder to the ureter
[38–40]) over the past 10 years [41–43]. Also, this identical
material is approved for SUI treatment in the European
UnionandCanadaunderthenameZuidex;itisnotapproved
in the United States (US) for SUI. Following transanal
submucosal injection of NASHA/Dx, the dextranomer
facilitates the ingrowth of ﬁbroblasts and collagen between
the microspheres as hyaluronic acid is degraded. The bolus
is thus consolidated with endogenous tissue, stabilizing its
volume for a sustained durable response.
The purpose of this study was to evaluate the eﬃcacy and
safety of NASHA/Dx gel as an injectable bulking agent in the
treatment of FI. Safety was evaluated for a total of 12 months
after the last treatment.
2. Methods
This was an open-label, Noncomparative, one group,
prepostdesign, 15-center study performed in Europe and
Canada. A total of 115 eligible patients (100 female, 15
male) with a mean age of ∼62 years (range 30–80 years)
suﬀeringfrom FI were treatedwith NASHA/Dx gel (Table 1).
Informed consent was obtained from patients prior to
initiation of any study-related activities. The study was
conducted in accordance with the World Medical Associ-
ation Recommendations Guiding Physicians in Biomedical
Research Involving Human Patients amended by the 52nd
WorldMedicalAssociation(WMA)GeneralAssembly,Edin-
burgh, Scotland 2000 [44], and the notes of clariﬁcation on
paragraphs 29 and 30 dated 2002 and 2004, respectively [45–
47]. The protocol was approved by the Ethics Committee
of each hospital involved in the study. Collection of data,
organization and construction of the database, and all
statistical analyses and outputs were performed and retained
Table 1: Patient demographics.
(n = 115)
Female n (%) 100 (87.0)
Male n (%) 15 (13.0)
Age, years Mean (range) 62.5 (30.5–80.3)
Body mass index, kg/m2 Mean (range) 26.2 (16.6–41.5)
n: number of patients; %: percent of study analyzed safety population.
by the sponsor. The statistician involved in the analysis is
an employee of the sponsor. All authors had access to the
database and clinical study report and assume responsibility
for the completeness and accuracy of the content of the
paper. Approximately two thirds of the patients had been
symptomatic for <5years,andthemost commonunderlying
cause of the FI was attributed to obstetric injuries (32%
of patients) closely followed by neurogenic cause (30%).
Patients were screened for baseline data and eligibility at a
screening visit up to 12 weeks before the ﬁrst treatment visit.
3. Inclusion Criteria
At screening, the investigator interviewed the patient regard-
ing the existence of FI deﬁned as the inability to control
loose or solid stool as well as the severity of FI, to obtain
the baseline CCFIS. Eligible patients were adults of ages
18–80 suﬀering from FI (i.e., a Cleveland Clinic Florida
Incontinence Score (CCFIS) ≥5 at baseline and ≥4F I
episodes over a 28-day period as recorded in a patient diary).
The duration of FI prior to inclusion had to be ≥12 months,
and the patients must have failed conservative treatment.
4. Exclusion Criteria
Patients were excluded from the study if they were not
determined to suﬀer from FI and had anal or rectal malfor-
mation, prolapse, ﬁssures, rectal varices, stenosis, implants,
or complete external sphincter disruption. Likewise, patients
with a history of anorectal surgery within the last 12 months,
or previous stapled transanal rectal resection (STARR) or
stapled hemorrhoidectomy <2cm above the dentate line,
were excluded. Patients with histories of anorectal tumors,
malignancies, or chemotherapy within the last 6 months
prior to the study, or previous radiation therapy with signs
of radiation injury in the area to be treated, were excluded
from the study.
Patients with a medical history of human immunodeﬁ-
ciency virus (HIV) infection or any condition with severe
compromised immune defense, or on immunosuppressive
therapy,bleedingdiathesisoronanticoagulanttherapy(such
as warfarin, heparin, or heparin-like substance), anorectal
sepsis, anorectal bleeding, and active Inﬂammatory Bowel
Disease (IBD), and women that were pregnant or breast-
feeding, of childbearing potential not practicing adequate
contraception or planning to stop such contraception within
the ﬁrst year of the study or 6 months after partum, were also
excluded from participation in the study.Gastroenterology Research and Practice 3
5. Study Design
Eligible patients received 4 injections of 1mL NASHA/Dx
gel. Endoanal ultrasound was performed as a part of the
physical exam at screening to assess the intactness of the
sphincter. Bowel evacuation by ﬂeet enema was compulsory
prior to treatment. The use of local anesthetic was optional,
and the need for prophylactic antibiotics was determined by
the investigator.
Theinjectionswereperformedthroughananoscope,and
the NASHA/Dx gel was placed in the deep submucosal layer
of the anal canal approximately 5–10mm above the dentate
line at the anorectal junction. Injection was done at ∼30◦
angle, and the needle was kept in place for 15–30 seconds, to
prevent premature leakage of the solution over the puncture
opening.
One month after the ﬁrst treatment visit, the patients
were oﬀered retreatment of up to 4 × 1mL NASHA/Dx
gel, provided that the criteria for retreatment were fulﬁlled.
To be eligible for retreatment, the patient had to remain
incontinent according to the patient’s FI diary; have no
persistent adverse eﬀect; have no other medical reason
against retreatment; be willing to receive retreatment. The
optional retreatment was meant to enable individual adjust-
ment of the dose. If the patient was continent according to
patient’s diary and had improved to his/her satisfaction, no
retreatment was to be performed.
T h en u m b e ro fF Ie p i s o d e sp e r2 4h o u r sw a sr e c o r d e d
in the diaries. The recordings were speciﬁed as leakage of at
least 2mL solid or loose stool. Gas or stainings were not to
be recorded. The words “at least 2mL” were repeated on each
page of the diary so it was quite clear to the patients what
should be recorded. Controlled bowel movements without
accidents, urgency (need to hurry to the toilet) and use
of bowel medication (antidiarrhea drugs, such as Imodium
[loperamide] and Lomotil [diphenoxylate/atropine]), ﬁber
products, and others were recorded. There were no record-
ings of gas or staining only. The number of incontinence-
free days was also collected from the patient diaries. For a
Diary to be considered valid, at least 21 days must have been
completed with ≥3 FI episodes recorded, and the diary must
have been ﬁlled in according to the instructions on the diary.
Primary eﬃcacy was based on the assessment of FI
episodes (loose or solid stool, not gas) and was measured by
proportionofrespondersat12monthsafterlasttreatment.A
responder was deﬁned as a patient with ≥50% decrease from
baseline in the number of FI episodes (28-day patient diary
data)ofsolidorloosestool.Additionaleﬃcacyevaluationsat
6 and 12 months after last treatment included a change from
baseline in the CCFIS [48, 49] and achange from baseline
in Fecal Incontinence Quality of Life Scale (FIQL) [50]i n
countries where FIQL was available. Response in CCFIS was
deﬁned as having ≥30% reduction in CCFIS compared to
baseline. The choice to use cut points of a 50% reduction
from baseline in number of FI episodes and a >30% reduc-
tion in the CCFIS score, as thresholds, was to be consistent
with that of other published reports and as the authors
agreed that changes of this magnitude would represent a
clinically meaningful change to the patients [36, 51].
The safety population was deﬁned as all patients who
weretreatedwithstudyproduct.Allanalyseswereperformed
on the safety population.
6.Safety
The safety of NASHA/Dx gel treatment was measured
by the incidence, relationship, and severity of treatment
emergent adverse events (AEs) reported during the study.
Followup visits were performed at 1, 6, and 12 months
after the last treatment. At followup visits, rigid proctoscopy
(or ﬂexible sigmoidoscopy) was performed, and patients
were assessed for the presence or absence of AEs. Any
changes in concomitant medications were recorded. The
fecal incontinence Diary was collected, and a new diary was
distributed.
7.StatisticalMethods
T h es a m p l es i z eo f∼100 patients was not based on a
statistical calculation. Using a sample size of 100 patients
(∼7 patients from each center), the maximum length of the
95% conﬁdence interval (i.e., units) for the proportion of
responders at 12 months was 20 percentage units (occurs at
a proportion of 50% responders). By including 100 patients,
there was approximately 99% probability to observe at least
1 event of an AE with a hypothetical prevalence of 4.5%
and approximately 63% probability when the prevalence is
1%. Hence, 100 patients lead to a reasonable precision in the
eﬃcacyestimatesandalsofacilitateﬁndingsofadverseevents
that are less common. The primary eﬃcacy objective was to
calculate the proportion of responders based on a change
from baseline in the total number of incontinence episodes
at 12 months, together with a 2-sided 95% conﬁdence
interval based on the normal approximation to the binomial
distribution. The variable number of FI episodes had no
upper limit, and therefore the Wilcoxon one-sample test was
used to assess change from baseline together with a 2-sided
95% conﬁdence interval based on the normal approximation
to the binomial distribution. Continuous variables with a
limit on minimum and maximum outcome (i.e., CCFIS,
FIQL, incontinence-free days, number of days with antidiar-
rheal medication, and number of antidiarrheal medication
doses) were analyzed using a onesample t-test (change from
baseline) together with a 2-sided 95% conﬁdence interval
assuming normality. All tests were performed at the 5%
signiﬁcance level. P-values ≤ .05 were considered statistically
signiﬁcant. No adjustment of P-values for multiple testing
was performed.
8.Handlingof MissingData
Primary analyses were based on observed data. However,
a last-observation-carried-forward (LOCF) technique was
also used where the last performed eﬃcacy assessment was
carried forward to impute any subsequent missing values.
Diary data for visit 3 (i.e., at 1 month) was however not
used. If no eﬃcacy assessments were available neither at the4 Gastroenterology Research and Practice
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Figure 1: Disposition of patients.
baseline nor at any followup visit, the assessment and the
change from pretreatment value were missing in the analysis.
Partly missing data in the patient diary was handled as
follows. If incontinence data were completed for ≥14 days,
the number of FI episodes was scaled to number per 28
days in the following manner; (A) the number of FI episodes
observed, divided by number of days with incontinence data,
multiplied by 28. (B) The number of incontinence-free days
was scaled in a similar manner. If <14 days of incontinence
datawerecompleted,theincontinencedataatthattimepoint
was regarded as missing and handled according to the rules
above.
Partially missing data in 1 of the 5 domains in CCFIS
was left missing. Missing data for questions included in the
FIQL was handled as follows. If ≥50% of the questions in
1 domain were completed, the mean value of the completed
items replaced the missing responses. Consequently, if <50%
of the questions in 1 domain were completed, the domain
was regarded as missing and handled according to the rules
above.
9. Results
Of the 115 patients treated with NASHA/Dx gel, a total of
14 patients withdrew or were lost to followup at 6 months
(n = 101), and additional 10 patients withdrew or were
lost to followup at 12 months (n = 91). Of the 24 patients
that withdrew or were lost to followup, 13 withdrew consent,
7 were lost to followup, 3 withdrew for other reasons,
and 1 patient withdrew due to an AE (see Figure 1). All
enrolled patients (i.e., 115) received at least 1 treatment with
NASHA/Dxgel,and38(33%)patientsreceivedanadditional
(2nd) treatment.
Protocol deviations were considered to be major if they
would potentially inﬂuence the primary eﬃcacy results (i.e.,
the evaluation of number of FI episodes and subsequent
responder rates at 12 months). In total, 27 protocol devia-
tions in 25 patients were classiﬁed as major. The 25 patients
aﬀe c t e db yt h em a j o rp r o t o c o ld e v i a t i o n sw e r ee x c l u d e d
from the per-protocol analysis of the primary objective at
12 months. Only patients with valid diaries at both baseline
and at 12 months were included in the primary analysis.
In total, 86 patients (i.e., 74.8% of the analyzed safety
population) had evaluable diaries both at baseline and at the
12month visit and were consequently included in the ﬁnal
primary eﬃcacy analysis. At baseline, the number of patients
recording a valid patient diary was 114; this number was
reduced to 100 patients at 6 months and 88 patients at 12
months. Since one patient had a missing diary at baseline,
change from baseline could only be calculated for 99 and 87
patients at 6 and 12 months, respectively. Since one patient
had a value of zero FI episodes at baseline, responder rates
could only be calculated for 98 and 86 patients at 6 and
12 months, respectively. The patient recorded zero episodes
at baseline but treated because they claimed having had
more episodes in interview with the investigator. However,
the diary, which was source data, was never changed. This
incident was classiﬁed as major deviation, and the patient
remainedinthestudyforethicalreasonsandsafetyfollowup.
At 6 months after last treatment, 56 out of 98 (57.1%)
evaluable patients had ≥50% reduction from baseline in the
number of FI episodes. At 12 months, the responder rate was
64.0% when based on observed cases in the analyzed safety
population. The excluded patients comprised 5 patients with
invalid FI diaries at baseline or at the 12-month visit and 24
patients who withdrew study participation prior to the 12-
month visit. All eﬃcacy data at 6 months are summarized in
Table 2,a n da l le ﬃcacy data at 12 months are summarized in
Table 3.
The reduction from baseline in number of FI episodes,
recorded in the 28-day diary, was statistically signiﬁcant at
both 6 months (P<. 001) and 12 months (P<. 001)
after last treatment. When based on observed cases in the
analyzed safety population, the median change from baseline
in number of FI episodes at 6 months was −7.0 (−58.9%)
episodes (baseline 16.0). The median change from baseline
in number of FI episodes at 12 months was −7.6 (−70.2%)
episodes (baseline 15.0).
The increase in mean number of incontinence-free
days was signiﬁcantly higher at 6 and 12 months after
treatment compared to baseline (P<. 001 at both 6 and
12 months). The mean change from baseline was +6.9 and
+7.1 incontinence-free days at 6 and 12 months after last
treatment, respectively. The mean number of incontinence-
free days was 20.9 at 6 months and 21.2 at 12 months after
last treatment.
There was a statistically signiﬁcant (P<. 001) reduction
from baseline in number of controlled bowel evacuations
where the patients had to hurry to the toilet (as recorded in
the 28-day diary) at 6 months (i.e., −6.1 instances); and the
reduction from baseline was sustained at 12 months (P<
.001) (i.e., −7.5 instances).
Improvement from baseline in Cleveland Clinic Florida
Incontinence Score was statistically signiﬁcant at both 6
months (P<. 001) and 12 months (P<. 001). In patientsGastroenterology Research and Practice 5
Table 2: Changes from baseline at 6 months.
Baseline 6 months Change from
baseline P-value
Patients with ≥50% decrease from baseline in number of
FI episodes, n(%), SE 0 56 (57.1)
0.050
56 (57.1)
0.050 N/A
Total number of FI episodes, mean (SE) 20.8 (1.71) 11.1 (1.84) −9.7 (1.71) <.001∗∗
Total number of solid FI episodes, mean (SE) 9.5 (1.28) 5.7 (1.28) −3.9 (1.32) <.001∗∗
Total number of loose FI episodes, mean (SE) 11.3 (1.21) 5.4 (0.78) −5.8 (1.14) <.001
Total number of FI-free days, mean (SE) 14.0 (0.73) 20.9 (0.73) 6.9 (0.73) <.001∗
Number of controlled bowel evacuations, mean (SE) 22.5 (2.07) 27.0 (2.31) 4.5 (1.86) .015∗
Cleveland Clinic Florida Incontinence Score, mean (SE) 13.5 (0.36) 9.2 (0.50) −4.3 (0.47) <.001∗
Fecal Incontinence Quality of Life (FIQL) Scores
Lifestyle, mean (SE) 2.4 (0.10) 3.0 (0.10) 0.5 (0.10) <.001∗
Coping/behavior, mean (SE) 1.8 (0.07) 2.3 (0.09) 0.6 (0.10) <.001∗
Depression/self perception, mean (SE) 2.6 (0.10) 3.1 (0.10) 0.5 (0.09) <.001∗
Embarrassment, mean (SE) 1.8 (0.08) 2.5 (0.10) 0.6 (0.10) <.001∗
SE: standard error.
∗One-sample t-test; ∗∗Wilcoxon onesample test.
Table 3: Changes from baseline at 12 months.
Baseline 12 months Change from
baseline P-value∗
Patients with ≥50% decrease from baseline in number of FI
episodes, n(%), SE 0 55 (64.0)
0.052
55 (64.0)
0.052 N/A
Total number of FI episodes, mean (SE) 20.6 (1.90) 9.6 (1.81) −11.0 (1.90) <.001∗∗
Total number of solid FI episodes, mean (SE) 9.6 (1.41) 3.8 (0.85) −5.9 (1.52) <.001∗∗
Total number of loose FI episodes, mean (SE) 10.9 (1.32) 5.9 (1.49) −5.1 (1.67) <.001
Total number of FI-free days, mean (SE) 14.1 (0.81) 21.2 (0.88) 7.1 (0.94) <.001∗
Number of controlled bowel evacuations, mean (SE) 23.0 (2.18) 24.4 (2.41) 1.5 (1.81) .315∗
Cleveland Clinic Florida Incontinence Score, mean (SE) 13.4 (0.36) 8.7 (0.50) −4.7 (0.48) <.001∗
Fecal Incontinence Quality of Life (FIQL) Scores
Lifestyle, mean (SE) 2.4 (0.10) 2.9 (0.09) 0.5 (0.10) <.001∗
Coping/behavior, mean (SE) 1.7 (0.07) 2.4 (0.11) 0.7 (0.11) <.001∗
Depression/self perception, mean (SE) 2.7 (0.10) 3.2 (0.10) 0.5 (0.11) <.001∗
Embarrassment, mean (SE) 1.8 (0.08) 2.6 (0.11) 0.8 (0.11) <.001∗
SE: standard error.
∗One-sample t-test; ∗∗Wilcoxon onesample test.
evaluable at both baseline and at 6 months (analyzed Safety
Population, OC), the mean CCFIS was reduced from 13.5 at
baseline to 9.2 at 6 months. Similarly, the mean CCFIS was
reduced from 13.4 at baseline to 8.7 at 12 months.
The Fecal Incontinence Quality of Life (FIQL) question-
naire is divided into 4 domains: lifestyle, coping/behavior,
depression/self perception, and Embarrassment. The lower
the FIQL score, the lower quality of life. Statistically sig-
niﬁcant increases from baseline were observed at 6 and 12
months for all 4 FIQL domains. The results in the individual
domains are summarized in Tables 2 and 3.
A total of 154 AEs were reported by 70 patients during
the study. Of these events, 79 were assessed as related to the
study treatment. The majority of the treatment-related AEs
(94.9%) were assessed to be of mild or moderate intensity
and most (92.4%) were classiﬁed as nonserious. Nearly all
(98.7%) of AEs were resolved spontaneously, or following
treatment,withoutsequelae.Atotalof20AEs,reportedby14
patients, were classiﬁed as serious. Six serious AEs (reported
by 4 patients) that were deemed as possibly related to the
study treatment comprised one case each of perineal abscess,
rectovaginal septum abscess, and rectal abscess, as well as
a case of concurrent rectal prolapse, proctalgia, and rectal
hemorrhage. One patient died due to cardiac failure and was
reported as a serious AE and determined to be unrelated to
the study treatment. The most prevalent AEs (i.e., ≥3 events)
are presented in Table 4.
Fever was fairly common after treatment. A total of
7% of patients reported pyrexia that were assessed by the
investigator as related to treatment. All of these events6 Gastroenterology Research and Practice
Table 4: Related AEs with an incidence of >3 events by MedDRA preferred term: safety population.
MedDRA
preferred term
Number
of events
Maximal intensity Median
time to
onset
Median
duration
Method of intervention∗ Proportion
of events
resolved Mild Moderate Severe None
required
Medical
treatment Other
Adominal pain 3 1 2 0 1.0 8.0 1 2 0 100%
Constipation 5 4 1 0 2.0 3.0 1 4 0 100%
Diarrhea 5 2 3 0 1.0 8.0 3 2 0 100%
Injection site
pain 4 2 2 0 1.0 3.0 0 4 0 100%
Perineal pain 3 1 2 0 1.0 6.0 1 2 0 100%
Proctalgia 15 7 7 1 0.0 5.0 9 5 1∗ 100%
Pyrexia 8 3 4 1 1.0 3.5 2 6 0 100%
Rectal
hemorrhage 3210 1 3 . 0 4 . 0 20 1 ∗ 100%
Rectal tenesmus 3 3 0 0 0.0 8.0 3 0 0 100%
MedDRA: medical dictionary of regulatory authorities.
∗One event each of proctalgia and rectal hemorrhage were coinciding events with a rectal prolapse that was treated in surgery.
commenced shortly after treatment and all resolved within a
weekoftheonset.Twoeventsrequirednotreatment;5events
were treated with antipyretics or anti-inﬂammatory agents
and only 1 event with antibiotics.
A total of 6 cases of anorectal abscess were reported in
the study. Three of these events commenced within the 1st
week after treatment, 2 during the 3rd week after treatment,
and 1 event after 130 days. All of these events resolved after
treatment. In 3 cases, the abscess was incised and drained,
followed by treatment with antibiotics. In the remaining
3 cases, no local surgical exploration was performed, and
the patient was treated with antibiotics only. In the single
instancewherematerialwassentformicrobiologicalcultures
the results showed bacteroides fragilis. None of the patients
developing abscess received prophylactic antibiotics prior
NASHA/Dx injection.
10. Discussion
Currently, the injection of bulk-enhancing agents into the
anal canal area for the treatment of FI is considered in
its infancy [52]. Several diﬀerent types of agents have
been investigated (i.e., collagen, silicon beads, carbon beads,
and NASHA/DX), and the results of these trials reveal
low complication rates and a mild-to-moderate eﬀect on
incontinence symptom improvement [32–36].
Danielson and colleagues have reported on the use of
NASHA Dx gel as an injectable anal canal implant for the
treatment of FI [36]. The results of their study demonstrated
a 50% reduction in the number of incontinence episodes
compared with pretreatment values in 44% of treated
patients at 6 months and 56% of treated patients at 12
months. In that study, no long-term side eﬀects or serious
adverse events were reported.
In the current study, the majority of patients were
improved after treatment with NASHA/Dx gel. The propor-
tion of patients having ≥50% reduction in number of FI
episodeswas57.1%at6monthsaftertreatmentand64.0%at
12monthsaftertreatment,indicatingthattheachievedeﬀect
is sustained for up to a year. This conclusion is supported by
the observations in mean change from baseline in number
of FI days were similar at 6 and 12 months after treatment;
59.2% and 65.1%, respectively. The treatment eﬀect was
also conﬁrmed in analyses of the CCFIS. In addition to the
frequencyofFIepisodes,thisscalealsoincludesotheraspects
of the disease such as lifestyle alteration and use of pads. The
mean CCFIS was signiﬁcantly lower at 6 and 12 months after
treatment compared to baseline, and the reduction observed
after 6 months remained at 12 months after treatment.
Moreover, a similar pattern was observed for the patients’
results in Fecal Incontinence Quality of Life instrument.
All four domains measured by the FIQL were improved at
6 months after treatment, and the eﬀect remained at 12
months after treatment. A number of the AEs related to
treatment were indicative of perioperative infection which is
not unexpected with treatments procedures in the anorectal
region [53]. The results of safety and eﬃcacy assessments
noted in this trial are consistent with the results of a previous
trial by Danielson et al. [36].
The NASHA/Dx gel (i.e., Solesta) used in this trial is
the same substance marketed in the EU and Canada under
the name Zuidex and is approved in those arenas for the
treatment of SUI. In the US, this same substance (marketed
under the name of Deﬂux) is approved for the treatment
of VUR in children. It is not approved in the US for the
treatment of SUI.
Therehavebeenseveralreportsoftheformationofsterile
abscesses associated with the use of Zuidex in the treatment
of women with SUI [54–56]. The formation of sterile
abscesses in women with SUI following surgical intervention
(tension-free vaginal tape, intervaginal slingplasty, etc.) is
quite common [57–84]. However, in the pediatric popula-
tion, the safety of NASHA/Dx gel (i.e., Deﬂux) for the treat-
ment of VUR has been demonstrated to be quite good with
very few reports of sterile abscess formation [29, 37, 85–87].Gastroenterology Research and Practice 7
When considering the safety of NASHA/Dx gel for the
treatment of FI, as is the case in this clinical trial and in a
previous study by Danielson et al. [36], correlations between
the safety proﬁles of Zuidex in the treatment of women with
SUI, or Deﬂux in children for the treatment of VUR are
diﬃcult to make. This is due in part to the safety proﬁles
associated with each product, the naturally high incidence of
abscess formation in the treatment of women with SUI, the
diﬀerences in patient populations and indications for usage,
and the diﬀerences of application site. What is clear is the
need for future long-term safety studies in the application of
NASHA/Dx gel in the treatment of FI.
11. Limitations
Since the study did not include any reference arm it is not
possible to determine the extent of placebo eﬀect in the
use of NASHA/Dx gel in the treatment of FI. Since no
placebo arm was, included it is not possible to determine
whether the observed proportions of related/unrelated AEs
reﬂectunderreportingofunrelatedAEs.Inaddition,novalid
stool consistency scale was used to better understand the
exact nature of each patient’s FI. In some cases, speciﬁc data
points were missing, and the LOCF method was employed
to impute missing data. Also validated pain scores and/or
patient satisfaction scales may have added to the overall
assessmentofSolestaasanovelclinicaloptionforFIpatients.
12. Conclusions
The results of this study indicate that the use of NASHA/Dx
gelwaseﬃcaciousinthetreatmentofFI.Thetreatmenteﬀect
was signiﬁcant at 6 months and lasted up to 12 months after
treatment, both in reduction of number of FI episodes and
disease-speciﬁc quality of life. An additional advantage for
the use of NASHA/Dx gel as a treatment for FI as opposed
to treatment with injectable silicone biomaterial (PTQ) or
Injectable synthetic calcium hydroxylapatite ceramic micro-
spheres (Coaptite) is that it does not require the use of
anesthesia.
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